RIPK1
Receptor-interacting serine/threonine-protein kinase 1
As of the edition of 20 October 2026, RIPK1 (receptor-interacting serine/threonine-protein kinase 1, UniProt Q13546) has 8 drugs tested at it and 7 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13546
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 40
- Disease areas
- Immune system; Nervous system; Nutrition and metabolism; Skin and connective tissue; Digestive system; Bones, joints and muscles; Cancer; Heart and blood vessels
- Registered trials of its drugs
- 31
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Went quiet | 1 |
| Stopped | 5 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| GSK2982772 | Went quiet | Phase 2 | none listed |
| Oditrasertib | Stopped | Phase 2 | none listed |
| Ocadusertib | Active | Phase 2 | none listed |
| Eclitasertib | Active | Phase 2 | none listed |
| GFH312 | Stopped | Phase 2 | none listed |
| DNL747 | Stopped | Phase 1 | none listed |
| Flizasertib | Stopped | Phase 2 | none listed |
| GSK3145095 | Stopped | Phase 2 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 3 |
| Undetermined | 1 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| GSK | Route A |
| Roche | Route A |
| Denali Therapeutics | Route A |
The other 4 companies at RIPK1
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at RIPK1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.